In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53 (Q64073233)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

title

In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

0 references

0 references

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Julie Jacobs

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

author name string

Jolien Van den Bossche

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Ines De Pauw

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Hilde Lambrechts

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Christophe Hermans

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Vanessa Deschoolmeester

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Pol Specenier

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Patrick Pauwels

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Jan Baptist Vermorken

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Marc Peeters

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Filip Lardon

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

An Wouters

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

language of work or name

English

0 references

publication date

5 April 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

page(s)

1196-1213

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

28 April 2020

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6487694/fullTextXML

inferred from PubMed Central ID database lookup

cites work

DNA damage is able to induce senescence in tumor cells in vitro and in vivo.

1 reference

12 December 2020

Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease

1 reference

12 December 2020

Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies

1 reference

12 December 2020

Tumor cell senescence in cancer treatment

1 reference

12 December 2020

Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals

1 reference

12 December 2020

Normal cells, but not cancer cells, survive severe Plk1 depletion

1 reference

12 December 2020

Targeting polo-like kinase 1 for cancer therapy.

1 reference

12 December 2020

Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers?

1 reference

12 December 2020

Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia

1 reference

12 December 2020

Targeted anti-mitotic therapies: can we improve on tubulin agents?

1 reference

12 December 2020

p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells

1 reference

12 December 2020

Polo-like kinase 1 is involved in invasion through extracellular matrix

1 reference

12 December 2020

BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity

1 reference

12 December 2020

Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model

1 reference

12 December 2020

Targeted therapies in the treatment of advanced/metastatic NSCLC.

1 reference

12 December 2020

Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability

1 reference

12 December 2020

Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells

1 reference

12 December 2020

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

1 reference

12 December 2020

Therapy-induced senescence in cancer

1 reference

12 December 2020

p53-dependent repression of polo-like kinase-1 (PLK1).

1 reference

12 December 2020

PLK1 as an oncology target: current status and future potential

1 reference

12 December 2020

Reciprocal influence of the p53 and the hypoxic pathways

1 reference

12 December 2020

Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies

1 reference

12 December 2020

Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer

1 reference

12 December 2020

High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder

1 reference

12 December 2020

p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors

1 reference

12 December 2020

Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.

1 reference

12 December 2020

Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays

1 reference

12 December 2020

Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway

1 reference

12 December 2020

Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.

1 reference

12 December 2020

Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma.

1 reference

12 December 2020

In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors

1 reference

12 December 2020

Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

1 reference

12 December 2020

Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma

1 reference

12 December 2020

Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation

1 reference

12 December 2020

Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy

1 reference

12 December 2020

A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1

1 reference

12 December 2020

Plk1-targeted therapies in TP53- or RAS-mutated cancer

1 reference

12 December 2020

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

1 reference

12 December 2020

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy

1 reference

12 December 2020

Non-small-cell lung cancers: a heterogeneous set of diseases

1 reference

12 December 2020

BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.

1 reference

12 December 2020

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

1 reference

12 December 2020

Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.

1 reference

12 December 2020

Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines

1 reference

12 December 2020

Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells

1 reference

12 December 2020

Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia

1 reference

12 December 2020

Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines

1 reference

12 December 2020

Mutant p53 expression in fallopian tube epithelium drives cell migration

1 reference

12 December 2020

Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment

1 reference

12 December 2020

The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer

1 reference

12 December 2020

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.

1 reference

12 December 2020

Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma

1 reference

12 December 2020

APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines

1 reference

12 December 2020

Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling.

1 reference

12 December 2020

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor

1 reference

12 December 2020

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

1 reference

12 December 2020

MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer

1 reference

12 December 2020

Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines

1 reference

12 December 2020

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo

1 reference

12 December 2020

Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.

1 reference

12 December 2020

Towards Prognostic Profiling of Non-Small Cell Lung Cancer: New Perspectives on the Relevance of Polo-Like Kinase 1 Expression, the TP53 Mutation Status and Hypoxia

1 reference

12 December 2020

The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis

1 reference

12 December 2020

Decreased KPNB1 Expression is Induced by PLK1 Inhibition and Leads to Apoptosis in Lung Adenocarcinoma

1 reference

12 December 2020

Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1002/1878-0261.12477

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30859681%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

PubMed publication ID

30859681

1 reference